Compare Stocks: GELS, BFRI, ABVC, and COCP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.02 +1.9%	$1.17	$0.71 ▼ $3.40	$26.62M	0.61	104,466 shs	2,345 shs
BFRI Biofrontera	$1.53 +1.3%	$1.23	$0.55 ▼ $1.61	$22.72M	0.83	382,491 shs	1,129 shs
COCP Cocrystal Pharma	$1.13 -0.4%	$1.03	$0.76 ▼ $2.67	$21.67M	1.48	64,468 shs	29,248 shs
GELS Gelteq	$0.78 -13.2%	$0.59	$0.39 ▼ $2.02	$8.53M	-0.41	2.56 million shs	398,383 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+15.67%	+25.68%	-6.54%	-24.81%	-63.10%
BFRI Biofrontera	-0.66%	+1.34%	+23.77%	+61.50%	+73.56%
COCP Cocrystal Pharma	-2.59%	-0.88%	+15.28%	+17.18%	-23.39%
GELS Gelteq	+27.60%	+56.67%	+67.39%	+79.72%	-20.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.02 +1.9%	$1.17	$0.71 ▼ $3.40	$26.62M	0.61	104,466 shs	2,345 shs
BFRI Biofrontera	$1.53 +1.3%	$1.23	$0.55 ▼ $1.61	$22.72M	0.83	382,491 shs	1,129 shs
COCP Cocrystal Pharma	$1.13 -0.4%	$1.03	$0.76 ▼ $2.67	$21.67M	1.48	64,468 shs	29,248 shs
GELS Gelteq	$0.78 -13.2%	$0.59	$0.39 ▼ $2.02	$8.53M	-0.41	2.56 million shs	398,383 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	+15.67%	+25.68%	-6.54%	-24.81%	-63.10%
BFRI Biofrontera	-0.66%	+1.34%	+23.77%	+61.50%	+73.56%
COCP Cocrystal Pharma	-2.59%	-0.88%	+15.28%	+17.18%	-23.39%
GELS Gelteq	+27.60%	+56.67%	+67.39%	+79.72%	-20.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
BFRI Biofrontera	2.00	Hold	N/A	N/A
COCP Cocrystal Pharma	1.00	Sell	N/A	N/A
GELS Gelteq	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GELS, BFRI, ABVC, and COCP Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/21/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/15/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/29/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/26/2026	GELS Gelteq	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	GELS Gelteq	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/8/2026	COCP Cocrystal Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	52.25	N/A	N/A	$0.46 per share	2.17
BFRI Biofrontera	$41.71M	0.54	N/A	N/A	$0.40 per share	3.78
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.05 per share	N/A
GELS Gelteq	$110K	86.97	N/A	N/A	$1.08 per share	0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.30	N/A	N/A	N/A	N/A	-47.68%	-30.97%	11/16/2026 (Estimated)
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
COCP Cocrystal Pharma	-$8.83M	-$0.76	N/A	N/A	N/A	N/A	-207.47%	-123.33%	11/13/2026 (Estimated)
GELS Gelteq	-$4.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest GELS, BFRI, ABVC, and COCP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/13/2026	Q2 2026	COCP Cocrystal Pharma	-$0.17	-$0.23	-$0.06	-$0.23	$0.11 million	$0.11 million
8/12/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	-$0.03	+$0.37	-$0.03	$0.11 million	N/A
6/30/2026	Q2 2026	GELS Gelteq	N/A	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
GELS Gelteq	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.07	0.07
BFRI Biofrontera	0.78	1.18	1.08
COCP Cocrystal Pharma	N/A	1.24	1.24
GELS Gelteq	N/A	0.09	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
BFRI Biofrontera	10.08%
COCP Cocrystal Pharma	6.72%
GELS Gelteq	N/A

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
BFRI Biofrontera	8.10%
COCP Cocrystal Pharma	39.40%
GELS Gelteq	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.65 million	21.59 million	Not Optionable
BFRI Biofrontera	70	14.85 million	13.65 million	No Data
COCP Cocrystal Pharma	10	19.26 million	11.67 million	Not Optionable
GELS Gelteq	N/A	10.71 million	N/A	N/A

GELS, BFRI, ABVC, and COCP Headlines

Recent News About These Companies

Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

July 2, 2026 | stockhouse.com

Gelteq Limited Advances Clinical Programs and Asia Expansion in First Half of 2026

June 30, 2026 | tipranks.com

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs

June 17, 2026 | globenewswire.com

Gelteq Limited: Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq Technology for Animal Health Applications

June 13, 2026 | finanznachrichten.de

Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating ...

June 12, 2026 | caledonianrecord.comC

What's going on with Gelteq stock Friday?

June 12, 2026 | msn.com

Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications

June 12, 2026 | globenewswire.com

Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion

June 4, 2026 | globenewswire.com

Gelteq Calls June 19 Special Meeting to Approve Potentially Dilutive Convertible Note Share Issuance

June 2, 2026 | tipranks.com

Gelteq Limited: Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway

May 20, 2026 | finanznachrichten.de

Gelteq startet klinische Studie für antiparasitäres Tierarzneimittel

May 20, 2026 | de.investing.com

Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway

May 20, 2026 | globenewswire.com

Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA

May 14, 2026 | accessnewswire.comA

Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth

May 12, 2026 | globenewswire.com

Gelteq Limited

April 15, 2026 | edition.cnn.com

Gelteq Limited Ordinary Shares (GELS) Real-Time

April 10, 2026 | nasdaq.com

Healthy Extracts Reports 2025 Net Revenue Up 45% to Record $4.5 Million

April 8, 2026 | accessnewswire.comA

Healthy Extracts Reports Preliminary 2025 Results, Net Revenue Expected Up 45% to Record $4.5 Million

April 2, 2026 | accessnewswire.comA

Gelteq Warned by Nasdaq Over Minimum Bid Price Compliance

March 24, 2026 | tipranks.com

Gelteq Limited and Healthy Extracts Inc. Sign Strategic Partnership to Launch Gel-Based Nutraceutical Products

February 11, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS, BFRI, ABVC, and COCP Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$1.02 +0.02 (+1.90%)

As of 09:45 AM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Biofrontera NASDAQ:BFRI

$1.53 +0.02 (+1.32%)

As of 09:43 AM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Cocrystal Pharma NASDAQ:COCP

$1.12 -0.01 (-0.44%)

As of 09:43 AM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Gelteq NASDAQ:GELS

$0.78 -0.12 (-13.23%)

As of 09:46 AM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GELS, BFRI, ABVC, and COCP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GELS, BFRI, ABVC, and COCP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GELS, BFRI, ABVC, and COCP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS, BFRI, ABVC, and COCP Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Biofrontera NASDAQ:BFRI

Cocrystal Pharma NASDAQ:COCP

Gelteq NASDAQ:GELS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GELS, BFRI, ABVC, and COCP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GELS, BFRI, ABVC, and COCP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GELS, BFRI, ABVC, and COCP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS, BFRI, ABVC, and COCP Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Biofrontera NASDAQ:BFRI

Cocrystal Pharma NASDAQ:COCP

Gelteq NASDAQ:GELS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools